Carmot Therapeutics
Improving Diabetes Therapy Through Innovation
Obesity is one of the major causes of insulin resistance, fatty liver disease and diabetes (NAFLD/NASH). Numerous studies have demonstrated that severely restricting caloric intake can reverse and even cure diabetes. Yet, no anti-diabetic drugs have weight loss as a central mechanism. The introduction of glp-1 receptor agonists has been one of the most significant break-throughs in diabetes therapy in the past decade. However, while GLP-1R agonists produce substantial weight loss in animal models, they only provide modest weight loss in humans. It was this disconnect that inspired Carmot Therapeutics to look further into the biology of GLP-1. The insights gained from these studies put Carmot Therapeutics on a path to develop better and more efficacious therapies for the treatment of diabetes, obesity and fatty liver disease. To identify drugs with the desired attributes, Carmot Therapeutics turned to our drug discovery technology called Chemotype Evolution. Chemotype Evolution was invented by Carmot and has revolutionized the ability to make and test new drug molecules. This allows to rapidly explore novel chemistry in the search for drug molecules with specific biological properties. Using this technology Carmot Therapeutics has identified compounds that modulate both GLP and GIP biological pathways in ways that the natural hormones are not capable off. Essentially Carmot has evolved drug molecules that retain beneficial properties of GLP1 and GIP while minimizing undesirable effects.